{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062234","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.010418+00:00","generated_at":"2026-06-08T06:57:15.246586+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aptevo enters warrant inducement to raise up to $3.4M, issues new warrants at $0.233","bullets":["Existing warrant holders agree to exercise up to 16,013,034 shares at $0.233 per share for up to ~$3.4M gross proceeds.","New Series A and B warrants issued for 200% of exercised shares, with exercise price $0.233; 50% immediately exercisable.","Proceeds to fund clinical development and working capital; A.G.P./Alliance Global Partners serves as financial advisor (7% fee).","New warrants subject to beneficial ownership limitations (4.99% or 9.99%); registration statement for resale to be filed by Nov 27, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062234","json":"https://secwatch.observer/filing/0000950170-23-062234.json","markdown":"https://secwatch.observer/filing/0000950170-23-062234.md","text":"https://secwatch.observer/filing/0000950170-23-062234.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023062234/0000950170-23-062234-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023062234/apvo-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:57:15.246586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"782de613f8241061a5c245aed772283b1fd49efc","claim":"Aptevo Therapeutics Inc. entered into Inducement Agreement with certain holders of existing Series A Common Stock Purchase Warrants and Series B Common Stock Purchase Warrants valued at up to approximately $3.4 million (effective 2023-11-09).","evidence_excerpt":"On November 9, 2023, Aptevo Therapeutics Inc. (the “Company”) entered into a warrant inducement agreement (the “Inducement Agreement”) with certain holders (the “Holders”) of the Company’s existing Series A Common Stock Purchase Warrants (“Existing Series A Warrants”) and Series B Common Stock Purchase Warrants (“Existing Series B Warrants” and together, the “Existing Warrants”) to purchase shares of common stock, par value $0.001 per share (the “Common Stock”), of the Company.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671584/000095017023062234/0000950170-23-062234-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain holders of existing Series A Common Stock Purchase Warrants and Series B Common Stock Purchase Warrants"},{"label":"Value","value":"up to approximately $3.4 million"},{"label":"Effective","value":"2023-11-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}